190 related articles for article (PubMed ID: 20110419)
1. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Aujay M; Ngo HT; Azab AK; Azab F; Quang P; Maiso P; Runnels J; Anderson KC; Demo S; Ghobrial IM
Blood; 2010 May; 115(20):4051-60. PubMed ID: 20110419
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
Parlati F; Lee SJ; Aujay M; Suzuki E; Levitsky K; Lorens JB; Micklem DR; Ruurs P; Sylvain C; Lu Y; Shenk KD; Bennett MK
Blood; 2009 Oct; 114(16):3439-47. PubMed ID: 19671918
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
Roccaro AM; Leleu X; Sacco A; Jia X; Melhem M; Moreau AS; Ngo HT; Runnels J; Azab A; Azab F; Burwick N; Farag M; Treon SP; Palladino MA; Hideshima T; Chauhan D; Anderson KC; Ghobrial IM
Blood; 2008 May; 111(9):4752-63. PubMed ID: 18316628
[TBL] [Abstract][Full Text] [Related]
5. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
Lee SJ; Levitsky K; Parlati F; Bennett MK; Arastu-Kapur S; Kellerman L; Woo TF; Wong AF; Papadopoulos KP; Niesvizky R; Badros AZ; Vij R; Jagannath S; Siegel D; Wang M; Ahmann GJ; Kirk CJ
Br J Haematol; 2016 Jun; 173(6):884-95. PubMed ID: 27071340
[TBL] [Abstract][Full Text] [Related]
6. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
Roccaro AM; Sacco A; Chen C; Runnels J; Leleu X; Azab F; Azab AK; Jia X; Ngo HT; Melhem MR; Burwick N; Varticovski L; Novina CD; Rollins BJ; Anderson KC; Ghobrial IM
Blood; 2009 Apr; 113(18):4391-402. PubMed ID: 19074725
[TBL] [Abstract][Full Text] [Related]
7. New C(4)- and C(1)-derivatives of furo[3,4-c]pyridine-3-ones and related compounds: evidence for site-specific inhibition of the constitutive proteasome and its immunoisoform.
Hovhannisyan A; Pham TH; Bouvier D; Piroyan A; Dufau L; Qin L; Cheng Y; Melikyan G; Reboud-Ravaux M; Bouvier-Durand M
Bioorg Med Chem Lett; 2014 Mar; 24(6):1571-80. PubMed ID: 24534487
[TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
Kuhn DJ; Hunsucker SA; Chen Q; Voorhees PM; Orlowski M; Orlowski RZ
Blood; 2009 May; 113(19):4667-76. PubMed ID: 19050304
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.
Chitta K; Paulus A; Akhtar S; Blake MK; Caulfield TR; Novak AJ; Ansell SM; Advani P; Ailawadhi S; Sher T; Linder S; Chanan-Khan A
Br J Haematol; 2015 May; 169(3):377-90. PubMed ID: 25691154
[TBL] [Abstract][Full Text] [Related]
10. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
Moreau AS; Jia X; Patterson CJ; Roccaro AM; Xu L; Sacco A; O'Connor K; Soumerai J; Ngo HT; Hatjiharissi E; Hunter ZR; Ciccarelli B; Manning R; Ghobrial IM; Leleu X; Treon SP
Br J Haematol; 2008 Sep; 142(5):775-85. PubMed ID: 18537966
[TBL] [Abstract][Full Text] [Related]
11. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S
Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973
[TBL] [Abstract][Full Text] [Related]
12. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.
Leleu X; Xu L; Jia X; Sacco A; Farag M; Hunter ZR; Moreau AS; Ngo HT; Hatjiharissi E; Ho AW; Santos DD; Adamia S; O'Connor K; Ciccarelli B; Soumerai J; Manning RJ; Patterson CJ; Roccaro AM; Ghobrial IM; Treon SP
Blood; 2009 Jan; 113(3):626-34. PubMed ID: 18981296
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
Moreau AS; Jia X; Ngo HT; Leleu X; O'Sullivan G; Alsayed Y; Leontovich A; Podar K; Kutok J; Daley J; Lazo-Kallanian S; Hatjiharissi E; Raab MS; Xu L; Treon SP; Hideshima T; Anderson KC; Ghobrial IM
Blood; 2007 Jun; 109(11):4964-72. PubMed ID: 17284528
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
[TBL] [Abstract][Full Text] [Related]
15. Targeting NF-kappaB in Waldenstrom macroglobulinemia.
Leleu X; Eeckhoute J; Jia X; Roccaro AM; Moreau AS; Farag M; Sacco A; Ngo HT; Runnels J; Melhem MR; Burwick N; Azab A; Azab F; Hunter Z; Hatjiharissi E; Carrasco DR; Treon SP; Witzig TE; Hideshima T; Brown M; Anderson KC; Ghobrial IM
Blood; 2008 May; 111(10):5068-77. PubMed ID: 18334673
[TBL] [Abstract][Full Text] [Related]
16. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
[TBL] [Abstract][Full Text] [Related]
17. Proteasome Inhibitors in Waldenström Macroglobulinemia.
Kastritis E; Dimopoulos MA
Hematol Oncol Clin North Am; 2018 Oct; 32(5):829-840. PubMed ID: 30190021
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Hideshima T; Chauhan D; Hayashi T; Podar K; Akiyama M; Mitsiades C; MItsiades N; Gong B; Bonham L; de Vries P; Munshi N; Richardson PG; Singer JW; Anderson KC
Cancer Res; 2003 Dec; 63(23):8428-36. PubMed ID: 14679006
[TBL] [Abstract][Full Text] [Related]
19. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
An J; Sun Y; Fisher M; Rettig MB
Mol Cancer Ther; 2004 Jun; 3(6):727-36. PubMed ID: 15210859
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
Powers GL; Ellison-Zelski SJ; Casa AJ; Lee AV; Alarid ET
Oncogene; 2010 Mar; 29(10):1509-18. PubMed ID: 19946334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
